What Do 2026 Phase II Studies Show About Sonefpeglutide's Effects on MASH Histology and Fibrosis Markers?
Phase II data for sonefpeglutide — a long-acting GLP-1/GIP/glucagon triple receptor co-agonist — demonstrate clinically meaningful reductions in hepatic steatosis, NAS score components, and fibrosis stage in biopsy-confirmed MASH. MRI-PDFF liver-fat reduction exceeded 50% relative from baseline at the highest doses, and a substantial proportion of participants achieved MASH resolution without fibrosis worsening, meeting the FDA's accepted surrogate histological endpoint.
What Is Sonefpeglutide and How Does Its Triple Receptor Mechanism Differ from Approved Incretin Agents?
Sonefpeglutide (also designated NNC9204-1177) is a once-weekly subcutaneous peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Unlike tirzepatide's dual GIP/GLP-1 agonism or semaglutide's selective GLP-1 agonism, the added glucagon receptor component drives direct hepatic fat oxidation and thermogenesis, providing a mechanistic rationale for superior liver-specific efficacy in MASH.
GLP-1 receptor activation suppresses hepatic de novo lipogenesis and reduces appetite-driven caloric surplus, the dominant driver of steatosis accumulation. GIP receptor co-agonism amplifies insulin secretion in a glucose-dependent manner and modulates adipose tissue lipid flux, reducing the free fatty acid delivery that fuels hepatic triglyceride synthesis. Together these two axes produce the weight-loss and glycaemic improvements documented across the incretin class.
The glucagon receptor component is the mechanistically distinctive element for MASH. Glucagon receptor activation in hepatocytes directly upregulates fatty acid β-oxidation via CPT1 induction and stimulates ketogenesis, providing a calorie-independent route to hepatic fat clearance. This pathway is particularly relevant in MASH because hepatic steatosis and the downstream lipotoxic cascade — generating reactive oxygen species, activating hepatic stellate cells, and promoting collagen deposition — can persist even after partial weight loss.
The pegylation strategy that gives sonefpeglutide its "peg" designation extends the plasma half-life to approximately one week, enabling once-weekly dosing. Pegylation also reduces immunogenicity risk relative to unmodified peptide analogues and stabilises the molecule against dipeptidyl peptidase-4 cleavage, which would otherwise rapidly inactivate the GLP-1 pharmacophore.
What Histological Endpoints Were Used in Phase II and What Did the Biopsy Data Show?
The Phase II programme used paired liver biopsies scored by the NASH Clinical Research Network (CRN) system, with co-primary endpoints of MASH resolution (NAS ≥2 reduction with no worsening of fibrosis) and fibrosis improvement of ≥1 stage. Sonefpeglutide met both endpoints at the highest tested doses, with MASH resolution rates substantially exceeding placebo in the 24–48 week biopsy windows.
The NASH CRN histological scoring system grades three components: steatosis (0–3), lobular inflammation (0–3), and hepatocyte ballooning (0–2), summed as the NAS (NAFLD Activity Score, 0–8). A NAS reduction of ≥2 points without fibrosis worsening is the FDA-accepted surrogate endpoint for accelerated approval in MASH. Fibrosis is staged separately on a 0–4 scale, with stage 3 representing bridging fibrosis and stage 4 cirrhosis.
In the Phase II dose-ranging cohort, sonefpeglutide-treated participants showed statistically significant reductions across all three NAS components versus placebo. Hepatocyte ballooning — the histological marker most directly linked to hepatocyte lipotoxic injury — showed the largest proportional improvement, consistent with the glucagon-mediated reduction in intrahepatic lipid load. Lobular inflammation scores also declined, reflecting attenuation of the macrophage-driven inflammatory milieu that sustains fibrogenesis.
Fibrosis stage improvement of ≥1 stage was achieved in a significantly greater proportion of sonefpeglutide-treated participants than placebo controls. This is a more demanding endpoint than NAS reduction because fibrosis regression requires not only cessation of stellate cell activation but active matrix metalloproteinase-mediated collagen remodelling — a process that lags behind the resolution of steatohepatitis by weeks to months.
How Did MRI-PDFF Liver-Fat Data Correlate with Biopsy Outcomes?
MRI-PDFF (proton density fat fraction) served as a non-invasive co-endpoint and showed dose-dependent hepatic fat reduction exceeding 50% relative from baseline at the highest sonefpeglutide dose. The magnitude of MRI-PDFF reduction correlated directionally with biopsy-confirmed NAS improvement, supporting MRI-PDFF as a valid interim surrogate in this compound's development programme.
MRI-PDFF quantifies hepatic triglyceride content with high reproducibility and sensitivity to change, making it the preferred non-invasive imaging endpoint in MASH trials. A reduction of ≥30% relative from baseline is widely used as a threshold for clinically meaningful liver-fat response. Sonefpeglutide's highest-dose cohort substantially exceeded this threshold, with mean relative reductions in the 50–65% range across the treatment period.
The correlation between MRI-PDFF reduction and histological NAS improvement was statistically significant, though not perfectly concordant — a subset of participants with large MRI-PDFF reductions did not achieve full MASH resolution on biopsy, reflecting the contribution of inflammation and ballooning to NAS that is not captured by fat-fraction imaging alone. This dissociation underscores why paired biopsy remains the regulatory gold standard for MASH drug approval.
Liver stiffness measurement by vibration-controlled transient elastography (VCTE) provided complementary fibrosis data. VCTE-measured liver stiffness declined in parallel with fibrosis stage improvement on biopsy, adding non-invasive corroboration to the histological fibrosis signal. The concordance between VCTE and biopsy-based fibrosis staging was consistent with published validation data for this modality in MASH populations.
What Mechanisms Explain Sonefpeglutide's Fibrosis-Stage Improvement Signal?
Fibrosis regression with sonefpeglutide is mechanistically attributable to three converging pathways: glucagon-receptor-driven reduction of hepatic lipotoxic substrate, GLP-1-receptor-mediated suppression of TGF-β1 signalling in hepatic stellate cells, and weight-loss-dependent reduction in portal endotoxin flux. Together these reduce the fibrogenic stimulus while permitting matrix remodelling to proceed.
Hepatic stellate cells (HSCs) are the primary effectors of liver fibrosis. In the quiescent state they store vitamin A; upon activation by lipotoxic damage-associated molecular patterns (DAMPs), free fatty acid metabolites, and inflammatory cytokines, they transdifferentiate into myofibroblasts that synthesise type I and III collagen. GLP-1 receptor agonism has been shown in preclinical models to directly inhibit HSC activation by suppressing TGF-β1 transcription and downstream SMAD2/3 phosphorylation.
The glucagon receptor axis contributes to fibrosis regression indirectly by reducing the intrahepatic lipid burden that generates the ceramide and diacylglycerol species responsible for mitochondrial dysfunction and DAMP release. Reducing lipotoxic substrate removes the upstream fibrogenic signal, allowing the anti-fibrotic matrix metalloproteinase programme to gain relative dominance over collagen synthesis.
Weight loss itself — mediated through the combined anorectic effects of GLP-1 and GIP receptor activation — reduces portal delivery of bacterial lipopolysaccharide from the gut microbiome. LPS activates hepatic Kupffer cells via TLR4, driving TNF-α and IL-6 production that sustains HSC activation. Reducing this portal endotoxin flux therefore attenuates the paracrine fibrogenic stimulus independently of direct hepatocyte lipotoxicity.
What Does the Phase II Safety Profile Reveal About Tolerability at Histologically Active Doses?
Sonefpeglutide's Phase II safety profile at doses producing histological improvement was dominated by gastrointestinal adverse events — nausea, vomiting, and diarrhoea — consistent with the incretin class. Rates were dose-dependent and concentrated in the dose-escalation phase. No hepatotoxicity signal was identified; liver enzyme trajectories were favourable, with ALT and AST declining in parallel with histological improvement.
Nausea was the most frequently reported adverse event, occurring in approximately 30–50% of participants at the highest doses during escalation, declining to 10–20% at steady state. This pattern mirrors the GI tolerability profile of semaglutide and tirzepatide and reflects GLP-1 receptor activation in the area postrema and gastrointestinal tract. Dose-escalation protocols that extend the titration period reduce peak nausea incidence without compromising ultimate efficacy.
Gallbladder-related adverse events — including cholelithiasis and cholecystitis — warrant monitoring in any GLP-1-containing regimen, as GLP-1 receptor activation reduces gallbladder motility and bile acid cycling. The Phase II programme reported gallbladder events at rates consistent with the class, without a signal exceeding that observed with approved agents at comparable weight-loss magnitudes.
Hypoglycaemia risk was low in the predominantly non-diabetic MASH population enrolled in Phase II, consistent with the glucose-dependent mechanism of GIP and GLP-1 receptor-mediated insulin secretion. The glucagon receptor component theoretically provides a counter-regulatory glycaemic buffer, though this was not formally tested as a mechanistic endpoint in the Phase II design.
How Does the June 2026 Licensing Update Position Sonefpeglutide Within the MASH Drug Development Landscape?
A June 2026 licensing agreement centred on sonefpeglutide reflects commercial validation of its Phase II biopsy-based signal. The deal positions the compound within a competitive MASH landscape where resmetirom (FDA-approved March 2024) has established the first histological approval benchmark, and multiple incretin-based agents are advancing through Phase II–III with biopsy co-endpoints.
Resmetirom (Rezdiffra), a liver-directed thyroid hormone receptor-β agonist, received FDA approval in March 2024 as the first drug approved specifically for MASH with fibrosis, based on 52-week biopsy data from the MAESTRO-NASH trial. Its approval established the regulatory precedent that histological endpoints — MASH resolution and fibrosis improvement — are sufficient for accelerated approval, lowering the evidentiary bar for subsequent agents with comparable biopsy data.
Semaglutide's Phase III MASH programme (ESSENCE trial) reported 72-week biopsy data in 2024, demonstrating MASH resolution in approximately 63% of treated participants versus 34% placebo, with fibrosis improvement in 37% versus 22%. These data established GLP-1 receptor agonism as a validated histological mechanism in MASH, providing a mechanistic anchor for the triple-agonist hypothesis underlying sonefpeglutide's development rationale.
The licensing deal's timing — following Phase II histological readouts — suggests the acquiring party assessed the biopsy signal as sufficiently robust to justify Phase III investment. In the MASH development landscape, Phase II biopsy data are the critical gating event for licensing, because the cost and complexity of Phase III paired-biopsy trials (typically 800–1,500 patients, 48–72 week treatment, with two biopsies per participant) requires high confidence in the histological signal before commitment.
What Are the Principal Methodological Limitations of the Phase II Evidence Base?
The Phase II evidence base for sonefpeglutide carries four principal limitations: modest sample sizes per dose cohort (typically 30–80 participants), treatment durations of 24–48 weeks that may underestimate fibrosis regression kinetics, the absence of an active comparator arm, and the inherent sampling variability of liver biopsy that introduces measurement noise into the primary endpoint.
Liver biopsy sampling variability is a well-documented methodological challenge in MASH trials. A single core biopsy samples approximately 1/50,000th of total liver volume, and histological heterogeneity within the MASH liver means that NAS scores can vary by 1–2 points between adjacent cores. This variability inflates the variance of the primary endpoint and requires larger sample sizes to achieve adequate statistical power — a constraint that Phase II designs typically accept in exchange for speed and cost efficiency.
The 24–48 week treatment duration in Phase II is sufficient to detect steatosis and inflammation changes but may underestimate the full fibrosis regression signal. Collagen remodelling in the liver proceeds over months to years; a 48-week biopsy captures early fibrosis regression but not the full trajectory. Phase III programmes typically extend to 72 weeks or longer to capture the fibrosis endpoint with greater fidelity.
The absence of an active comparator — such as semaglutide or tirzepatide — in the Phase II design means that the magnitude of sonefpeglutide's histological effect cannot be directly benchmarked against approved or advanced agents. Indirect comparisons across trials are confounded by differences in patient selection, baseline NAS and fibrosis stage, concomitant diabetes prevalence, and biopsy timing protocols. What Does 2026 Research Show About Tirzepatide in MASH: A Stack-Mapped Evidence Review? How Does Retatrutide's Triple Agonist Activity at GLP-1, GIP, and Glucagon Receptors Change Protocol Design for Weight Loss Versus Dual Agonists in 2026? How Does Tirzepatide Function as a Multi-Organ Metabolic Integrator, and What Do 2026 Molecular Mechanisms Mean for Body Composition?